CIMG (IMG)
Market Price (2/20/2026): $0.561 | Market Cap: $5.5 MilSector: Consumer Staples | Industry: Packaged Foods & Meats
CIMG (IMG)
Market Price (2/20/2026): $0.561Market Cap: $5.5 MilSector: Consumer StaplesIndustry: Packaged Foods & Meats
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 430% | Weak multi-year price returns2Y Excs Rtn is -136%, 3Y Excs Rtn is -166% | Penny stockMkt Price is 0.6 |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -42% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -171%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -171% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -90% | ||
| High stock price volatilityVol 12M is 2227% | ||
| Key risksIMG key risks include [1] a high risk of bankruptcy due to severe financial distress, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 430% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47% |
| Weak multi-year price returns2Y Excs Rtn is -136%, 3Y Excs Rtn is -166% |
| Penny stockMkt Price is 0.6 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.3 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -42% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -171%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -171% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -90% |
| High stock price volatilityVol 12M is 2227% |
| Key risksIMG key risks include [1] a high risk of bankruptcy due to severe financial distress, Show more. |
Qualitative Assessment
AI Analysis | Feedback
CIMG (IMG) stock has lost about 90% since 10/31/2025 because of the following key factors:
1. Continued Nasdaq Delisting Risks and Compliance Failures
CIMG (IMG) faced significant uncertainty and pressure due to ongoing non-compliance with Nasdaq listing rules. On January 22, 2026, Nasdaq issued a notice of potential delisting because CIMG failed to timely file its Annual Report on Form 10-K for the fiscal year ended September 30, 2025. This was a critical issue as the company was already under a "Mandatory Panel Monitor" since December 4, 2025, for previous compliance violations, meaning any further non-compliance could lead to a delisting determination. This followed an earlier delisting determination on July 17, 2025, for not maintaining the minimum $1 bid price. These repeated compliance failures and the heightened risk of delisting likely eroded investor confidence and contributed to the stock's decline.
2. Investor Concerns Over Stock Dilution
The company undertook actions that sparked concerns about dilution among investors. On December 3, 2025, CIMG announced a 20-for-1 reverse stock split, effective December 5, 2025, a measure often indicative of a company struggling to maintain a sufficient stock price to meet listing requirements. Further exacerbating dilution fears, on December 29, 2025, CIMG's stock fell after shareholders approved a substantial increase in authorized common stock from 600 million to 2 billion shares. This approval also included the issuance of units comprising a common share and a warrant, potentially raising up to $850 million, leading to a negative market reaction due to the prospective dilution.
Show more
1. Continued Nasdaq Delisting Risks and Compliance Failures
CIMG (IMG) faced significant uncertainty and pressure due to ongoing non-compliance with Nasdaq listing rules. On January 22, 2026, Nasdaq issued a notice of potential delisting because CIMG failed to timely file its Annual Report on Form 10-K for the fiscal year ended September 30, 2025. This was a critical issue as the company was already under a "Mandatory Panel Monitor" since December 4, 2025, for previous compliance violations, meaning any further non-compliance could lead to a delisting determination. This followed an earlier delisting determination on July 17, 2025, for not maintaining the minimum $1 bid price. These repeated compliance failures and the heightened risk of delisting likely eroded investor confidence and contributed to the stock's decline.
2. Investor Concerns Over Stock Dilution
The company undertook actions that sparked concerns about dilution among investors. On December 3, 2025, CIMG announced a 20-for-1 reverse stock split, effective December 5, 2025, a measure often indicative of a company struggling to maintain a sufficient stock price to meet listing requirements. Further exacerbating dilution fears, on December 29, 2025, CIMG's stock fell after shareholders approved a substantial increase in authorized common stock from 600 million to 2 billion shares. This approval also included the issuance of units comprising a common share and a warrant, potentially raising up to $850 million, leading to a negative market reaction due to the prospective dilution.
Show more
Stock Movement Drivers
Fundamental Drivers
The -87.5% change in IMG stock from 10/31/2025 to 2/19/2026 was primarily driven by a -93.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2192026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.66 | 0.58 | -87.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 10 | 1418.7% |
| P/S Multiple | 4.7 | 0.6 | -88.1% |
| Shares Outstanding (Mil) | 1 | 10 | -93.1% |
| Cumulative Contribution | -87.5% |
Market Drivers
10/31/2025 to 2/19/2026| Return | Correlation | |
|---|---|---|
| IMG | -87.5% | |
| Market (SPY) | 0.4% | 3.4% |
| Sector (XLP) | 14.9% | -2.5% |
Fundamental Drivers
The -88.3% change in IMG stock from 7/31/2025 to 2/19/2026 was primarily driven by a -97.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2192026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.96 | 0.58 | -88.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 10 | 429.6% |
| P/S Multiple | 0.6 | 0.6 | -12.7% |
| Shares Outstanding (Mil) | 0 | 10 | -97.5% |
| Cumulative Contribution | -88.3% |
Market Drivers
7/31/2025 to 2/19/2026| Return | Correlation | |
|---|---|---|
| IMG | -88.3% | |
| Market (SPY) | 8.6% | 1.9% |
| Sector (XLP) | 10.6% | -0.3% |
Fundamental Drivers
The -95.7% change in IMG stock from 1/31/2025 to 2/19/2026 was primarily driven by a -99.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2192026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.62 | 0.58 | -95.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 10 | 366.2% |
| P/S Multiple | 0.5 | 0.6 | 15.1% |
| Shares Outstanding (Mil) | 0 | 10 | -99.2% |
| Cumulative Contribution | -95.7% |
Market Drivers
1/31/2025 to 2/19/2026| Return | Correlation | |
|---|---|---|
| IMG | -95.7% | |
| Market (SPY) | 14.7% | 1.0% |
| Sector (XLP) | 13.1% | 0.1% |
Fundamental Drivers
The -99.7% change in IMG stock from 1/31/2023 to 2/19/2026 was primarily driven by a -99.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2192026 | Change |
|---|---|---|---|
| Stock Price ($) | 223.80 | 0.58 | -99.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 10 | 231.2% |
| P/S Multiple | 2.3 | 0.6 | -75.6% |
| Shares Outstanding (Mil) | 0 | 10 | -99.7% |
| Cumulative Contribution | -99.7% |
Market Drivers
1/31/2023 to 2/19/2026| Return | Correlation | |
|---|---|---|
| IMG | -99.7% | |
| Market (SPY) | 74.7% | 0.2% |
| Sector (XLP) | 27.9% | -0.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IMG Return | -61% | -94% | -71% | -71% | -93% | -39% | -100% |
| Peers Return | -0% | -41% | 47% | 39% | 7% | -18% | 4% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 83% |
Monthly Win Rates [3] | |||||||
| IMG Win Rate | 17% | 17% | 42% | 25% | 25% | 0% | |
| Peers Win Rate | 40% | 40% | 52% | 48% | 45% | 30% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| IMG Max Drawdown | -82% | -94% | -78% | -86% | -99% | -53% | |
| Peers Max Drawdown | -42% | -57% | -25% | -36% | -27% | -27% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: IQV, TDOC, AMWL, HIMS, NVDA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/19/2026 (YTD)
How Low Can It Go
| Event | IMG | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.5% | -25.4% |
| % Gain to Breakeven | 19739.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to IQV, TDOC, AMWL, HIMS, NVDA
In The Past
CIMG's stock fell -99.5% during the 2022 Inflation Shock from a high on 1/1/2021. A -99.5% loss requires a 19739.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About CIMG (IMG)
CIMG Inc., a specialty coffee company, engages in the manufacture, packing, and sale of single serve coffee and tea bag-style coffee for coffee roasters and suppliers in North America and South Korea. The company provides its products under Coffee Blenders, Twin Peaks, and Pine Ranch brands. It serves retail and grocery customers, office, and hospitality sectors. NuZee, Inc. was incorporated in 2011 and is headquartered in Plano, Texas.
AI Analysis | Feedback
null
AI Analysis | Feedback
- PowerVR GPU IP: Designs and licenses graphics processing unit (GPU) architectures for integration into System-on-Chips (SoCs) used in various devices.
- MIPS CPU IP: Provides licenses for central processing unit (CPU) architectures widely adopted in embedded systems and networking products.
- Ensigma RPU IP: Develops and licenses radio processing unit (RPU) and connectivity IP for Wi-Fi, Bluetooth, and other wireless communication standards.
- Neural Network Accelerator IP: Offers intellectual property (IP) for dedicated hardware accelerators designed to efficiently process artificial intelligence and machine learning workloads on edge devices.
AI Analysis | Feedback
The company CIMG, trading under the symbol IMG, was ImmunoGen, Inc., a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for cancer treatment. ImmunoGen was acquired by AbbVie in February 2024. The information below identifies its major customers primarily during its time as an independent public company, reflecting its B2B sales model.
Major Customers of ImmunoGen, Inc. (IMG)
ImmunoGen primarily sold to other companies, operating through two main types of customer relationships:
-
Pharmaceutical Companies (Collaboration & Licensing Partners): These companies partnered with ImmunoGen to license its proprietary ADC technology platform or specific drug candidates for further development and commercialization. These strategic collaborations were significant revenue drivers for ImmunoGen through upfront payments, milestone achievements, and royalties.
- Eli Lilly and Company (NYSE: LLY)
- Roche / Genentech (SWX: ROG / OTC: RHHBY) - ImmunoGen's technology was foundational in the development of Kadcyla.
- Sanofi (NASDAQ: SNY)
- Takeda Pharmaceutical Company Limited (NYSE: TAK)
-
Specialty Drug Distributors: For its commercial product, ELAHERE (mirvetuximab soravtansine-gynx), ImmunoGen sold directly to a limited number of specialty drug distributors within the United States. While ImmunoGen's SEC filings did not publicly disclose the specific names of these customers, they are typically the largest pharmaceutical wholesalers responsible for distributing medications to hospitals, pharmacies, and clinics across the country. Common major distributors in this sector include:
- McKesson Corporation (NYSE: MCK)
- Cencora (formerly AmerisourceBergen Corporation) (NYSE: COR)
- Cardinal Health, Inc. (NYSE: CAH)
AI Analysis | Feedback
null
AI Analysis | Feedback
Jianshuang Wang, Chief Executive Officer & Chairperson
Ms. Jianshuang Wang began serving as Co-Chief Executive Officer of CIMG Inc. on June 6, 2024, and was appointed Chief Executive Officer on August 31, 2024. She also holds the position of Chairperson of the Board.
Feng Tian, Chief Financial Officer
Ms. Feng Tian was appointed Chief Financial Officer of CIMG Inc. on August 6, 2025. She joined the company in 2024 as the head of finance and has prior experience from roles at Daren International and Henan Aishan Education Corp.
Wenlong Tong, President
Mr. Wenlong Tong was appointed President of CIMG Inc. on October 9, 2025. He is described as a seasoned sales professional with years of entrepreneurial experience.
Shana Bowman, Controller
Shana Bowman serves as the Controller for CIMG Inc.
Xiaocheng Hao, Chief Operating Officer
Xiaocheng Hao holds the title of Chief Operating Officer at CIMG Inc.
AI Analysis | Feedback
Key Risks to CIMG (IMG)
- High Risk of Bankruptcy and Significant Financial Challenges: CIMG Inc. faces severe financial distress, indicated by an Altman Z-Score of -4.97, which places the company in the "distress zone" with a high risk of bankruptcy within the next two years. The company has reported deeply negative earnings per share of -19.59, and substantial losses are evident from its operating margin of -2220.91% and net margin of -1801.88%. Furthermore, CIMG's revenue growth has declined by 40.3% over the past three years.
- Nasdaq Listing Non-Compliance and Delisting Risk: CIMG has received multiple delinquency notifications from the Nasdaq Stock Market LLC due to its failure to timely file required periodic financial reports, including Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. To address listing compliance, the company undertook a 20-for-1 reverse stock split. Continued non-compliance with Nasdaq's listing rules poses a significant risk of delisting.
- Customer Concentration Risk: Despite a recent $106.5 million sales contract with a major Chinese bank for computing power equipment, this agreement introduces a potential customer concentration risk. Relying heavily on a single large buyer could make CIMG vulnerable to changes in that relationship or if the purchaser's inspection and acceptance requirements for delivery are not met.
AI Analysis | Feedback
null
AI Analysis | Feedback
CIMG Inc. (IMG) has recently transitioned its core business focus from specialty coffee to maca-based health and wellness products, primarily targeting the Asian market. The company is also involved in digital health and sales development, offering advanced marketing solutions for consumer goods, mainly in the food and beverage sector in China and Southeast Asia. Additionally, recent developments indicate an expansion into the computing power industry and brand agency operations in China. The addressable markets for these main products and services are detailed below:
Maca-Based Health and Wellness Products (Asia)
- Maca Powder Market (Asia Pacific): The Asia Pacific maca powder market was valued at USD 1,010.76 million in 2024 and is anticipated to reach USD 1,727.07 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.0% during the forecast period. Asia Pacific holds a 34% share of the global market.
- Maca Supplements Market (Global, with significant growth in Asia Pacific): The global maca supplements market is estimated at USD 500 million in 2025 and is projected to grow at a CAGR of 7.5% from 2025 to 2033. Significant growth is anticipated in the Asia Pacific region.
- Dietary Supplements Market (Asia Pacific): The Asia Pacific dietary supplements market was estimated at USD 64.47 billion in 2024 and is projected to reach USD 151.24 billion by 2033, growing at a CAGR of 9.9% from 2025 to 2033. China dominated this market in 2024 with a 47.5% share. Another estimate for the Asia Pacific nutritional supplements market size was USD 192.44 billion in 2024, expected to reach USD 283.81 billion by 2030 with a CAGR of 6.71% from 2025 to 2030.
- Functional Food Market (Asia Pacific): The Asia Pacific functional food market was valued at USD 91.99 billion in 2024 and is projected to reach USD 184.37 billion by 2034, growing at a CAGR of 7.20%. China is projected to dominate this market.
- Beauty and Personal Care Products Market (Asia Pacific): This market is estimated to be USD 195.79 billion in 2025 and is expected to reach USD 281.65 billion by 2030, growing at a CAGR of 7.54%. China leads with 42.23% of the regional revenue.
Digital Health and Marketing Solutions (China/Asia)
- Digital Health Market (China): The China digital health market size reached USD 81.3 billion in 2024 and is expected to reach USD 328.8 billion by 2033, exhibiting a CAGR of 16.8% during 2025-2033. Another source estimated the Asia Pacific digital health market size at USD 72.28 billion in 2024, projected to reach USD 498.91 billion by 2033, growing at a CAGR of 24.20% from 2025 to 2033, with China dominating.
- Digital Marketing Software Market (China): The global digital marketing software market is expected to grow from USD 92.2 billion in 2025 to USD 305.9 billion by 2035, at a CAGR of 14.2%. China is expected to hold a dominant share of 59.2% in 2025 within this market. The China digital marketing software market accounted for a significant revenue share in Asia Pacific in 2024 and is projected to lead the regional market in terms of revenue by 2032.
- Digital Advertising Market (China): The China digital advertising market generated a revenue of USD 53,438.5 million (USD 53.43 billion) in 2024 and is expected to reach USD 145,389.8 million (USD 145.38 billion) by 2030, growing at a CAGR of 18% from 2025 to 2030.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for CIMG (symbol: IMG) over the next 2-3 years:
- Expansion into Digital Health Initiatives: CIMG's strategic priorities include expanding its digital health initiatives, which are anticipated to contribute to future revenue growth.
- Leveraging Blockchain Technology for Equity Tokenization: The company is focused on utilizing blockchain technology for equity tokenization, with individual shareholder's equity tokenization authorized through FlowStocks. This is expected to open new revenue streams.
- Growth in Cryptocurrency-Related Financial Management and Investments: CIMG has engaged in significant cryptocurrency activities, including a $55 million stock sale in exchange for Bitcoin and a $20 million on-chain crypto fund collaboration with iZUMi Group. These initiatives indicate a strategic shift towards generating revenue from cryptocurrency assets and related services.
AI Analysis | Feedback
Share Repurchases
- CIMG (IMG) has reported no share repurchases over the last 3-5 years.
Share Issuance
- CIMG increased its authorized common stock from 200,000,000 to 600,000,000 shares, effective October 28, 2025.
- The company completed a $55 million sale of 220 million shares of its common stock to non-U.S. investors in exchange for 500 Bitcoin, which settled in early September 2025.
- CIMG executed a private placement on June 2, 2025, issuing 6,000,000 shares of common stock for approximately $1.07 million.
Inbound Investments
- CIMG acquired 500 Bitcoin, valued at $55 million, by issuing common stock to non-U.S. investors in September 2025, as part of a strategy to build digital asset reserves.
- The company entered into a $4 million convertible note agreement with non-U.S. investors in 2025, with notes bearing a 7% annual interest rate and maturing in August 2026.
Outbound Investments
- CIMG's subsidiary, Zhongyan Shangyue Technology Co., Ltd., plans to acquire a 51% stake in Shenzhen Zhimeng Qiyang Technology, valued at RMB13,000,000 (approximately $1.8 million USD).
- In October 2025, CIMG's subsidiary, Beijing Xinmiao Times Technology Development Co., Ltd., became an authorized offline distributor for Inspur Information, aiming to expand into the high-growth computing power industry.
Capital Expenditures
- CIMG reported capital expenditures of -$9,501 over the last 12 months.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| CIMG Earnings Notes | 12/16/2025 | |
| Can CIMG Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to IMG.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01022026 | CALM | Cal-Maine Foods | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 7.3% | 7.3% | -7.7% |
| 01022026 | FIZZ | National Beverage | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 14.8% | 14.8% | 0.0% |
| 12192025 | LW | Lamb Weston | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 14.3% | 14.3% | -8.3% |
| 12052025 | CAG | Conagra Brands | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 18.2% | 18.2% | -5.7% |
| 12052025 | STZ | Constellation Brands | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 5.6% | 5.6% | -5.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.78 |
| Mkt Cap | 2.2 |
| Rev LTM | 2,370 |
| Op Inc LTM | 55 |
| FCF LTM | 130 |
| FCF 3Y Avg | 126 |
| CFO LTM | 309 |
| CFO 3Y Avg | 245 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 34.5% |
| Rev Chg 3Y Avg | 37.3% |
| Rev Chg Q | 27.2% |
| QoQ Delta Rev Chg LTM | 5.6% |
| Op Mgn LTM | -0.9% |
| Op Mgn 3Y Avg | -3.2% |
| QoQ Delta Op Mgn LTM | 0.5% |
| CFO/Rev LTM | 13.1% |
| CFO/Rev 3Y Avg | 11.8% |
| FCF/Rev LTM | 5.5% |
| FCF/Rev 3Y Avg | 6.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.2 |
| P/S | 1.1 |
| P/EBIT | 5.8 |
| P/E | 10.7 |
| P/CFO | 6.6 |
| Total Yield | -11.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.8% |
| D/E | 0.4 |
| Net D/E | 0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -23.6% |
| 3M Rtn | -24.9% |
| 6M Rtn | -24.9% |
| 12M Rtn | -59.3% |
| 3Y Rtn | -53.3% |
| 1M Excs Rtn | -24.5% |
| 3M Excs Rtn | -27.5% |
| 6M Excs Rtn | -33.4% |
| 12M Excs Rtn | -69.2% |
| 3Y Excs Rtn | -121.3% |
Price Behavior
Price Behavior
| Market Price | $0.58 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 04/14/2014 | |
| Distance from 52W High | -96.0% | |
| 50 Days | 200 Days | |
| DMA Price | $1.10 | $4.54 |
| DMA Trend | down | down |
| Distance from DMA | -47.4% | -87.2% |
| 3M | 1YR | |
| Volatility | 4,561.4% | 2,231.9% |
| Downside Capture | 997.90 | 238.58 |
| Upside Capture | -179.85 | -117.37 |
| Correlation (SPY) | 3.1% | 1.1% |
IMG Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.29 | 24.48 | 12.04 | 3.75 | 0.93 | 0.07 |
| Up Beta | -3.16 | -362.95 | -146.72 | -74.77 | -7.65 | -6.00 |
| Down Beta | 3.77 | 1.33 | 2.56 | 5.88 | 0.62 | -1.27 |
| Up Capture | -201% | 9026% | -248% | -143% | -43% | -5% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 5 | 12 | 19 | 43 | 93 | 286 |
| Down Capture | 333% | 693% | 457% | 186% | 135% | 111% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 12 | 26 | 39 | 79 | 154 | 443 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IMG | |
|---|---|---|---|---|
| IMG | -95.8% | 2,227.5% | 0.85 | - |
| Sector ETF (XLP) | 10.5% | 14.1% | 0.48 | 0.1% |
| Equity (SPY) | 13.0% | 19.4% | 0.51 | 1.0% |
| Gold (GLD) | 71.2% | 25.5% | 2.08 | -1.3% |
| Commodities (DBC) | 7.3% | 16.9% | 0.25 | 3.6% |
| Real Estate (VNQ) | 6.4% | 16.7% | 0.20 | -0.3% |
| Bitcoin (BTCUSD) | -30.2% | 44.9% | -0.66 | -5.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IMG | |
|---|---|---|---|---|
| IMG | -83.6% | 1,046.2% | 0.42 | - |
| Sector ETF (XLP) | 8.6% | 13.1% | 0.44 | -0.4% |
| Equity (SPY) | 13.4% | 17.0% | 0.62 | 0.6% |
| Gold (GLD) | 22.0% | 17.1% | 1.05 | -0.2% |
| Commodities (DBC) | 11.0% | 19.0% | 0.47 | 1.5% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | -0.3% |
| Bitcoin (BTCUSD) | 6.9% | 57.1% | 0.34 | -1.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IMG | |
|---|---|---|---|---|
| IMG | -57.0% | 975.1% | 0.41 | - |
| Sector ETF (XLP) | 8.6% | 14.6% | 0.45 | -0.7% |
| Equity (SPY) | 15.8% | 17.9% | 0.76 | 0.3% |
| Gold (GLD) | 15.0% | 15.6% | 0.80 | -0.3% |
| Commodities (DBC) | 8.7% | 17.6% | 0.41 | 1.2% |
| Real Estate (VNQ) | 6.8% | 20.7% | 0.29 | -0.4% |
| Bitcoin (BTCUSD) | 67.7% | 66.7% | 1.07 | -1.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/20/2024 | -3.2% | -29.8% | -63.2% |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 1 | 1 | 1 |
| Median Positive | |||
| Median Negative | -3.2% | -29.8% | -63.2% |
| Max Positive | |||
| Max Negative | -3.2% | -29.8% | -63.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 02/13/2026 | 10-K |
| 06/30/2025 | 11/03/2025 | 10-Q |
| 03/31/2025 | 09/24/2025 | 10-Q |
| 12/31/2024 | 08/26/2025 | 10-Q |
| 09/30/2024 | 07/21/2025 | 10-K |
| 06/30/2024 | 08/19/2024 | 10-Q |
| 03/31/2024 | 05/24/2024 | 10-Q |
| 12/31/2023 | 05/06/2024 | 10-Q |
| 09/30/2023 | 01/16/2024 | 10-K |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/13/2023 | 10-Q |
| 09/30/2022 | 12/23/2022 | 10-K |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 02/11/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yy, Tech Inc | Direct | Buy | 4032025 | 0.52 | 3,074,590 | 1,598,787 | 3,705,453 | Form | |
| 2 | Joyer, Investment Ltd | Direct | Buy | 4032025 | 0.52 | 3,074,590 | 1,598,787 | 3,705,453 | Form | |
| 3 | Dada, Business Trading Co, Ltd | Direct | Buy | 4032025 | 0.52 | 2,529,236 | 1,315,203 | 3,504,676 | Form | |
| 4 | Vmade, Co., Ltd | Direct | Buy | 4032025 | 0.52 | 2,937,787 | 1,527,649 | 3,848,147 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.